Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 728-733, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ward, W. K.
Right arrow Articles by Porte, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, W. K.
Right arrow Articles by Porte, D., Jr

Clinical Chemistry, Vol 32, 728-733, Copyright © 1986 by American Association for Clinical Chemistry

A sensitive radioimmunoassay for human proinsulin, with sequential use of antisera to C-peptide and insulin

WK Ward, TL Paquette, BH Frank and D Porte Jr

In this assay for immunoreactive human proinsulin (IRPI), it first is separated from plasma by use of an antiserum to human C-peptide. An immunoprecipitate is then formed by using a precipitating antiserum and polyethylene glycol, after which IRPI is dissociated from the antiserum by incubation in warm HCl, pH 2.0. The resulting mixture is assayed for insulin immunoreactivity by a double-antibody tracer-competition method involving incubation for four days with a high-affinity anti-insulin antiserum. Human proinsulin of recombinant-DNA origin is used as the standard. Added C-peptide at supraphysiological concentrations did not interfere with or react in the assay. Human insulin cross reacted by 1.5%. The detection limit for IRPI (2 SD from zero-dose binding) is 3 pmol/L. Proinsulin conversion intermediates are measured nearly as well as intact proinsulin. IRPI concentrations in 10 nondiabetic human subjects averaged 12.0 (SEM 1.6) pmol/L. The ratio of proinsulin to immunoreactive insulin averaged 14.3 (SEM 2.2)%. After intravenous arginine, the increase in proinsulin was less than that of insulin, and it declined more slowly.


The following articles in journals at HighWire Press have cited this article:


Home page
 DiabetesHome page
M. E. Roder and S. E. Kahn
Suppression of Beta-Cell Secretion by Somatostatin Does Not Fully Reverse the Disproportionate Proinsulinemia of Type 2 Diabetes
Diabetes, December 1, 2004; 53(suppl_3): S22 - S25.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Fritsche, A. Madaus, N. Stefan, O. Tschritter, E. Maerker, A. Teigeler, H. Haring, and M. Stumvoll
Relationships Among Age, Proinsulin Conversion, and {beta}-Cell Function in Nondiabetic Humans
Diabetes, February 1, 2002; 51(90001): S234 - 239.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Stumvoll, A. Fritsche, N. Stefan, E. Hardt, and H. Häring
Evidence against a Rate-Limiting Role of Proinsulin Processing for Maximal Insulin Secretion in Subjects with Impaired Glucose Tolerance and {beta}-Cell Dysfunction
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1235 - 1239.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Røder, R. S. Schwartz, R. L. Prigeon, and S. E. Kahn
Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2275 - 2280.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
P. Houssa, B. Dinesen, M. Deberg, B. H. Frank, C. Van Schravendijk, F. Sodoyez-Goffaux, and J.-C. Sodoyez
First direct assay for intact human proinsulin
Clin. Chem., July 1, 1998; 44(7): 1514 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Prigeon, S. E. Kahn, and D. Porte Jr.
Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 819 - 823.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Røder, D. Porte Jr., R. S. Schwartz, and S. E. Kahn
Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 604 - 608.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.